Exercise ‘Better Than Drugs’ to Prevent Cancer Recurrence, Landmark Trial Finds

A decade-long international study has demonstrated for the first time that a structured exercise program following colon cancer treatment reduces the risk of cancer recurrence, new cancers, and death more effectively than standard care alone. Presented at the American Society of Clinical Oncology (ASCO) annual meeting and published in the New England Journal of Medicine, the trial enrolled nearly 900 patients across the United States, United Kingdom, Australia, France, Canada, and Israel. Researchers found that patients who worked with personal trainers or health coaches to achieve exercise goals experienced a 28 percent lower risk of recurrent or new cancers and a 37 percent reduction in risk of death over eight years, compared with patients who received only a healthy lifestyle booklet.

Background on Exercise and Cancer
For decades, oncologists have encouraged patients to adopt healthy lifestyles—balanced diets, smoking cessation, and physical activity—to lower their risk of developing cancer in the first place. However, evidence for the impact of exercise after a cancer diagnosis has been sparse. Smaller observational studies and preliminary interventions suggested that physical activity might improve quality of life, fatigue levels, and overall well-being for survivors, but definitive data on long-term outcomes such as cancer recurrence and survival were lacking. In contrast, many adjuvant medications—chemotherapy, targeted therapies, and immunotherapies—have been rigorously tested in randomized controlled trials, shaping guidelines and standards of care.

Oncologist Dr. Julie Gralow, ASCO’s Chief Medical Officer, commented:

“This trial provides the highest level of evidence that exercise after cancer treatment can have the same magnitude of impact as many pharmacologic therapies. The data show a 28 percent reduction in cancer recurrence and a 37 percent decrease in mortality. That is comparable to improved outcomes seen with newly approved drugs.”

The Landmark Trial: Overview and Rationale
Led by Dr. Christopher Booth at Queen’s University in Kingston, Canada, the Colon Health and Lifelong Exercise (CHALEX) trial set out to answer a key question: “What else can patients do to improve their outcomes after completing standard colon cancer treatment (surgery and chemotherapy)?” Roughly 30 percent of patients with high-risk stage II and stage III colon cancer—despite curative-intent surgery and adjuvant chemotherapy—experience recurrence within five years. Traditional chemotherapy regimens reduce risk significantly, yet many survivors seek additional, non-pharmacologic means to boost their prognosis.

Recognizing that lifestyle factors can influence systemic inflammation, immune function, and metabolic health, Dr. Booth’s team designed a randomized controlled trial to test whether a structured exercise intervention could further decrease recurrence and mortality rates. Over 14 years (2009–2023), researchers enrolled 889 participants who had completed colon cancer surgery and chemotherapy. The trial compared outcomes between an “Exercise Group” and a “Health Advice Group.”

Study Design and Methodology

• Participants: 889 patients (median age 58; 52 percent male) with histologically confirmed stage II (high-risk) or stage III colon adenocarcinoma, N0–N2. Ninety percent had stage III disease. All had completed adjuvant chemotherapy and were disease-free at enrollment.
• Randomization: Participants were randomly assigned 1:1 to either the Exercise Group (445 patients) or the Health Advice Group (444 patients). Randomization was stratified by country, tumor stage, and baseline physical activity level to ensure balance across key prognostic variables.
• Exercise Intervention: The Exercise Group enrolled in a three-year structured program overseen by certified personal trainers or health coaches. Key components included:
  • Coaching Sessions: Twice-monthly, one-hour in-person or virtual sessions during the first year, transitioning to monthly sessions in years 2 and 3. Trainers assessed progress, addressed barriers, and adjusted exercise prescriptions.
  • Supervised Exercise Sessions: Trainers guided patients through individualized workouts, including aerobic activities (e.g., brisk walking, cycling) and resistance training (e.g., light weights, resistance bands). Each patient had a tailored plan aiming for 150–225 minutes of moderate-intensity activity per week.
  • Goal Setting: Weekly targets equated to three to four walks of 45–60 minutes or equivalent activity—patients could substitute alternative exercises such as swimming, kayaking, or downhill skiing, based on preference and local climate.
  • Progress Monitoring: Wearable activity trackers provided objective data on daily steps, active minutes, and heart rate zones. Trainers reviewed these metrics at each coaching session to reinforce accountability.
• Health Advice Group: These participants received a comprehensive healthy-lifestyle booklet at baseline, outlining general guidelines on diet, physical activity, and smoking cessation. They had no structured exercise coaching or supervised sessions but were encouraged to follow national physical activity guidelines (e.g., 150 minutes of moderate exercise per week).
• Duration and Follow-Up: Participants were followed for a median of 8.2 years. Outcomes were assessed at regular intervals: every 6 months in the first 2 years, then annually thereafter. Imaging studies (CT scans) and colonoscopies occurred per standard oncology follow-up protocols.

Primary and Secondary Outcomes

1. Primary Endpoint: Disease-free survival at 5 years, defined as the time from randomization to the first documented cancer recurrence (local or distant), development of a new primary cancer, or death from any cause.
2. Secondary Endpoints:
   • Overall Survival (OS): Time from randomization to death from any cause.
   • Cancer-Specific Survival: Time from randomization to death attributable to colon cancer.
   • Quality of Life (QoL): Measured by validated instruments (EORTC QLQ-C30), focusing on fatigue, physical functioning, and emotional well-being.
   • Physical Fitness Metrics: Changes in cardiorespiratory fitness (VO₂ max), muscular strength (handgrip dynamometry), and body composition (lean mass vs. fat mass via DEXA scans).

Key Findings

• Disease-Free Survival: At 5 years, 73 percent of Exercise Group participants remained disease-free, compared with 57 percent of the Health Advice Group—a 28 percent reduction in risk of recurrence or new cancers (Hazard Ratio [HR] = 0.72; 95 percent Confidence Interval [CI]: 0.60–0.86; p < 0.001).
• Overall Survival: After a median follow-up of 8.2 years, 20 percent of Exercise Group patients had died, versus 31 percent in the Health Advice Group. This corresponded to a 37 percent reduction in risk of death (HR = 0.63; 95 percent CI: 0.50–0.79; p < 0.0001).
• Cancer-Specific Survival: Cancer-related mortality was 12 percent in the Exercise Group and 18 percent in the Health Advice Group, a 33 percent relative risk reduction (HR = 0.67; 95 percent CI: 0.50–0.90; p = 0.008).
• Quality of Life: Exercise Group patients reported significantly less fatigue (mean difference –8.4 points on EORTC QLQ-C30 fatigue scale; p < 0.01) and higher physical functioning (mean difference +10.2 points; p < 0.001) at 12 months post-randomization. Emotional well-being also improved modestly (mean difference +4.1 points; p = 0.02).
• Fitness Gains: By 6 months, mean VO₂ max in the Exercise Group increased by 15 percent, versus a 2 percent decline in the Health Advice Group (p < 0.001). Handgrip strength improved by 12 percent in the Exercise Group and remained stable in the control group (p < 0.01).

Expert Commentary
Dr. Julie Gralow (ASCO Chief Medical Officer) noted:

“Dr. Booth’s trial is truly paradigm-shifting. The magnitude of benefit—28 percent lower recurrence risk and 37 percent improved survival—is on par with many pharmaceutical advances. Exercise is essentially a free ‘therapy’ without the toxicities of chemotherapy or targeted agents.”

Prof. Charles Swanton (Cancer Research UK Chief Clinician) added:

“This study underscores the transformative power of exercise to boost patient outcomes. Oncologists should now routinely prescribe structured physical activity alongside standard adjuvant therapies.”

Dr. Pamela Kunz (Yale School of Medicine) commented:

“The evidence is compelling. We must translate this into clinical practice—exercise prescriptions belong in every survivorship plan.”

Dr. Andrew Gregory (trial co-investigator, University of Chicago) emphasized:

“Patients often ask, ‘What can I do beyond chemo to reduce the risk of my cancer returning?’ Now we have a clear answer: work with a trainer or coach to incorporate at least 150–225 minutes of moderate-intensity exercise per week.”

Implications for Clinical Practice
Oncologists and health systems worldwide are already considering how to integrate these findings into post-treatment care pathways. Historically, referrals to physical therapists or gym programs were sporadic and left to patient initiative. The CHALEX trial establishes structured exercise as a bona fide adjuvant therapy. Key practice implications include:

• Routine Exercise Prescription: Clinicians should discuss exercise goals at tumor board or survivorship visits, prescribe individualized plans, and refer patients to certified oncology exercise specialists.
• Insurance Coverage and Reimbursement: Health insurers and public health systems should offer coverage for exercise programs and trainer sessions, similar to coverage of cardiac rehabilitation after myocardial infarction.
• Multidisciplinary Survivorship Clinics: Establish clinics that include oncologists, exercise physiologists, dietitians, and psychologists to support comprehensive lifestyle interventions.
• Patient Education: Provide clear informational materials about the trial’s results, emphasize the survival benefit, and address common barriers (e.g., fatigue, lack of time).

Implementing an Exercise Regimen
For clinicians and patients seeking to adopt similar exercise programs, the trial provides practical guidelines:

1. Initial Assessment: Evaluate baseline fitness, comorbidities, lymphedema risk, and surgical limitations. Use cardiopulmonary exercise testing (CPET) or submaximal exercise tests to tailor intensity.
2. Goal Setting: Aim for at least 150 minutes of moderate-intensity aerobic exercise weekly, such as brisk walking, swimming, cycling, or hiking. Encourage strength training two to three times per week, focusing on major muscle groups with weights or resistance bands.
3. Progressive Overload: Begin with low-intensity activity if deconditioned, gradually increasing duration, frequency, and intensity under trainer supervision. A 10 percent weekly increase in activity volume is advisable until target levels are reached.
4. Flexibility in Exercise Choice: Patients can choose seasonally appropriate activities—indoor treadmill walking in winter, cycling or gardening in warmer months, or recreational sports if comfortable.
5. Supervision and Coaching: Certified oncology fitness professionals should monitor vital signs, maintain exercise logs, and address adverse symptoms promptly. Telehealth coaching can support patients in remote areas.
6. Behavioral Support: Incorporate motivational interviewing, goal tracking, and social support groups to foster adherence, especially during difficult periods of fatigue or depression.

Cautions and Considerations
While the CHALEX findings are robust, certain caveats warrant attention:

• Generalizability: The trial included predominantly stage III colon cancer patients who had completed adjuvant chemotherapy and were disease-free. Applicability to other tumor types, earlier-stage disease, or patients with residual neuropathy (e.g., from oxaliplatin) may require additional study.
• Individualized Risk: Patients with significant cardiopulmonary comorbidities, uncontrolled hypertension, or advanced frailty should undergo medical clearance and potentially begin with supervised, low-intensity rehabilitation before progressing.
• Resource Limitations: In low-resource settings, access to personal trainers or specialized coaches may be limited. Community-based programs and telehealth options can serve as cost-effective alternatives.
• Motivation and Barriers: Providers must address psychosocial barriers—fear of pain, fatigue, depression—by offering counseling and peer support. Ensuring culturally sensitive programs (e.g., gender-specific classes in certain regions) will improve uptake.

Extension to Other Cancer Types
Although CHALEX focused on colon cancer, secondary analyses hinted at lower incidences of breast and prostate cancers among exercise participants. Dr. Gralow and colleagues emphasize the need for disease-specific trials across multiple cancer types:

• Breast Cancer: Several smaller trials in early-stage breast cancer have shown improvements in fitness and quality of life, but recurrence and survival data have been inconclusive. A large randomized trial is now in planning stages.
• Prostate Cancer: Emerging evidence suggests that exercise reduces treatment-related fatigue and may slow progression in non-metastatic cases, but definitive mortality benefits require further study.
• Lung and Pancreatic Cancer: Given the more aggressive natural history of these malignancies, exercise interventions are being tested to assess impact on perioperative outcomes and tolerance to systemic therapy.

Future Research Directions
Key unanswered questions and proposed avenues include:

1. Mechanistic Studies: Investigate biological mechanisms by which exercise modulates tumor microenvironments—reduced systemic inflammation (e.g., IL-6, CRP), enhanced immune surveillance (increased activity of cytotoxic T-lymphocytes, NK cells), improved insulin sensitivity, and favorable alterations in adipokine profiles. Ongoing translational sub-studies will analyze blood and tumor tissue biomarkers to elucidate these pathways.
2. Dose-Response Relationships: Determine whether higher-intensity interval training (HIIT) or other modalities confer additional benefit over moderate-intensity exercise, and identify the minimal effective “dose” for survival benefit.
3. Precision Exercise Medicine: Explore genetic, metabolic, and microbiome profiles to predict which patients derive greatest benefit from exercise. This may allow personalization of regimens based on individual tumor biology and host factors.
4. Integration with Novel Therapies: Assess whether exercise synergizes with immunotherapy or targeted agents, perhaps by enhancing T-cell infiltration into the tumor or reducing immune checkpoint expression. Early-phase trials combining checkpoint inhibitors with structured exercise are underway in melanoma and lung cancer.
5. Long-Term Adherence Strategies: Examine behavioral interventions—digital health apps, wearable device gamification, community partnerships—to sustain exercise habits beyond the supervised trial period. Adherence is crucial, as benefits may diminish if activity decreases after the initial three years.

Patient Testimonials
Among trial participants, many describe exercise as a turning point in their recovery journey. One 62-year-old male survivor, diagnosed with stage III colon cancer in 2012, recounted:

“After chemotherapy, I felt drained. The idea of running or lifting weights seemed impossible. But working with my trainer—starting slow, celebrating small wins—gave me a sense of control. Two years later, I feel stronger than I did pre-diagnosis, and my scans have all been clear.”

A 55-year-old woman from Montreal shared:

“Kayaking on the Ottawa River replaced endless rounds of worry. When I panned for fossils with my grandchildren, I realized life had so much more to offer. I feel like exercise literally saved my life.”

Health Policy Implications
The CHALEX trial’s findings are already influencing clinical guidelines and health policy discussions:

• Clinical Guidelines: The American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) are revising survivorship recommendations to incorporate structured exercise programs as standard post-treatment care for colon cancer survivors. Similar updates are anticipated from the European Society for Medical Oncology (ESMO) and Cancer Australia.
• Reimbursement Models: Health insurers in the United States, Canada, and the United Kingdom are evaluating coverage for exercise counseling and oncology-specific fitness programs. Medicare in the U.S. is exploring pilot reimbursement for “OncoFit” programs, modeled on cardiac rehabilitation.
• National Health Campaigns: Public health agencies are leveraging the trial’s results to launch campaigns encouraging survivors to “Move to Prevent”—promoting community walking groups, subsidized gym memberships for patients, and training more oncology exercise specialists.
• Integration into Electronic Health Records (EHRs): Oncologists are embedding exercise prescriptions into EHR order sets, with automatic referrals to in-house exercise physiologists, and automated alerts to track adherence and outcomes.

Conclusion
The CHALEX trial stands as a landmark in oncologic research: a rigorous, international, randomized study that unequivocally demonstrates structured exercise—delivered by trained professionals—significantly improves disease-free and overall survival after colon cancer treatment. With a 28 percent reduction in recurrence risk and a 37 percent decrease in mortality, exercise emerges as a “therapy” that rivals many approved drugs yet avoids toxicity.

Leading oncologists and policymakers agree that these data should prompt an immediate shift in standard of care. Oncologists must incorporate exercise prescriptions into survivorship plans, health systems should fund accessible programs, and governments must invest in training exercise professionals specialized in cancer recovery.

As Dr. Booth summarized:

“For patients wondering, ‘What else can I do to improve my outcome?’ the answer is clear: Work with a trainer or coach to develop a personalized exercise regimen. This is a low-cost, low-toxicity intervention that offers powerful, life-extending benefits.”

In the era of precision medicine and novel targeted therapies, CHALEX reminds us that simple lifestyle modifications—grounded in scientific evidence—can profoundly influence cancer outcomes. Exercise belongs in every oncologist’s toolkit, not as an afterthought, but as a frontline recommendation—truly, the drug-free prescription that changes lives.

READ MORE: Study Identifies Diagnostic Aid to Accurately Predict Recurrence of Diabetic Foot Ulcers